PT - JOURNAL ARTICLE AU - Nilles, Eric J. AU - de St. Aubin, Michael AU - Dumas, Devan AU - Duke, William AU - Etienne, Marie Caroline AU - Abdalla, Gabriela AU - Jarolim, Petr AU - Oasan, Timothy AU - Garnier, Salome AU - Iihoshi, Naomi AU - Lopez, Beatriz AU - de la Cruz, Lucia AU - Puello, Yosanly Cornelio AU - Baldwin, Margaret AU - Roberts, Kathryn W. AU - Peña, Farah AU - Durski, Kara AU - Sanchez, Isaac Miguel AU - Gunter, Sarah M. AU - Kneubehl, Alexander R. AU - Murray, Kristy O. AU - Lino, Allison AU - Strobel, Sarah AU - Baez, Amado Alejandro AU - Lau, Colleen L. AU - Kucharski, Adam AU - Gutiérrez, Emily Zielinski AU - Skewes-Ramm, Ronald AU - Vasquez, Marietta AU - Paulino, Cecilia Then TI - Integrated SARS-CoV-2 serological and virological screening across an acute fever surveillance platform to monitor temporal changes in anti-spike antibody levels and risk of infection during sequential waves of variant transmission — Dominican Republic, March 2021 to August 2022 AID - 10.1101/2022.10.24.22281399 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.24.22281399 4099 - http://medrxiv.org/content/early/2022/11/07/2022.10.24.22281399.short 4100 - http://medrxiv.org/content/early/2022/11/07/2022.10.24.22281399.full AB - The global SARS-CoV-2 immune landscape and population protection against emerging variants is largely unknown. We assessed SARS-CoV-2 antibody changes in the Dominican Republic and implications for immunological protection against variants of concern. Between March 2021 and August 2022, 2,300 patients with undifferentiated febrile illnesses were prospectively enrolled. Sera was tested for total anti-spike antibodies and simultaneously collected nasopharyngeal samples for acute SARS-CoV-2 infection with RT-PCR. Geometric mean anti-spike titers increased from 6.6 BAU/ml (95% CI 5.1–8.7) to 1,332 BAU/ml (1055–1,682). Multivariable binomial odds ratios for acute SARS-CoV-2 infection were 0.55 (0.40–0.74), 0.38 (0.27–0.55), and 0.27 (0.18–0.40) for the second, third, and fourth versus the first anti-S quartile, with similar findings by viral strain. Integrated serological and virological screening can leverage existing acute fever surveillance platforms to monitor population-level immunological markers and concurrently characterize implications for emergent variant transmission in near real-time.Competing Interest StatementEJN is the PI on a US CDC funded U01 award that funded the study, and CLL, AK, DD, MdSA, SG, MCE, WD, NI, GA, MB, KWR, KD, and MV have received salary support, consultancy fees, or travel paid through this award. EZG and BL are employees of the US CDC. CT, LC, IMS, FP, and RSR are employees of the Ministry of Ministry of Health and Social Assistance, Dominican Republic, that was subcontracted with funds from the US CDC award. AK is supported by the Welcome Trust, UK. We declare no other competing interests.Funding StatementThe study was funded by the US CDC through a U01 award (PI EJN)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the National Council of Bioethics in Health, Santo Domingo (013-2019), the Institutional Review Board of Pedro Henriquez Urena National University, Santo Domingo, and the Mass General Brigham Human Research Committee, Boston, USA (2019P000094).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.